CORT Stock Summary and Trading Ideas (Corcept Therapeutics | NASDAQ:CORT)

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.

Corcept Therapeutics trades on the NASDAQ stock market under the symbol CORT.

As of December 18, 2025, CORT stock price declined to $81.54 with 807,418 million shares trading.

CORT has a beta of -0.17, meaning it tends to be less sensitive to market movements. CORT has a correlation of 0.00 to the broad based SPY ETF.

CORT has a market cap of $8.59 billion. This is considered a Mid Cap stock.

Last quarter Corcept Therapeutics reported $208 million in Revenue and $.16 earnings per share. This fell short of revenue expectation by $-11 million and exceeded earnings estimates by $.01.

In the last 3 years, CORT traded as high as $117.33 and as low as $17.86.

The top ETF exchange traded funds that CORT belongs to (by Net Assets): IJR, VTI, VB, VBK, VXF.

CORT has outperformed the market in the last year with a return of +55.6%, while the SPY ETF gained +16.6%. However, in the most recent history, CORT shares have underperformed the stock market with its stock returning +2.2% in the last 3 month period and -3.7% for the last 2 week period, while SPY has returned +2.7% and -1.2%, respectively.

CORT support price is $80.13 and resistance is $84.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CORT shares will trade within this expected range on the day.